Skip to main
VVOS

Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics (VVOS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivos Therapeutics is a medical technology company that has reported strong gross margin growth and continues to develop its channel. Additionally, the company has revised their estimates and needs additional capital to fund operations. They have the potential for growth through accretive acquisitions and partnerships with sleep centers, showcasing early promise with their SCN integration. However, risks to their share price target include balance sheet and liquidity risks, as well as competition and changing market factors.

Bears say

Vivos Therapeutics is facing challenges with their transition from a legacy VIP/dentist model to the sleep-center model, leading to weakness in revenue growth in Q4. Additionally, their financials show a steady increase in shares outstanding, indicating the potential need for more financing in the near future. While their revenue did grow in 2025, there are concerns about their ability to compete in the market, secure capital and achieve sustainable profitability. The company must also address operational challenges and potential share dilution in order to meet previously projected growth.

Vivos Therapeutics (VVOS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivos Therapeutics (VVOS) Forecast

Analysts have given Vivos Therapeutics (VVOS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Vivos Therapeutics (VVOS) has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivos Therapeutics (VVOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.